Ipamorelin vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | Ipamorelin | Teriparatide |
|---|---|---|
| Mechanism | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
Both Ipamorelin and Teriparatide are commonly used for: